Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in adolescents with paroxysmal nocturnal hemoglobinuria
2024-516350-22-00Phase 2Authorised
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2024
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoints: Pharmacokinetics of pegcetacoplan, Change in hemoglobin and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2024-516350-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516350-22-00.